BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 3062082)

  • 1. Ursodeoxycholic acid for chronic liver diseases.
    Podda M; Ghezzi C; Battezzati PM; Bertolini E; Crosignani A; Petroni ML; Zuin M
    J Clin Gastroenterol; 1988; 10 Suppl 2():S25-31. PubMed ID: 3062082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
    Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
    Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
    Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
    Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration.
    Crosignani A; Podda M; Battezzati PM; Bertolini E; Zuin M; Watson D; Setchell KD
    Hepatology; 1991 Dec; 14(6):1000-7. PubMed ID: 1959845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
    Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
    Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
    Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
    Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of different doses of ursodeoxycholic acid in chronic liver disease.
    Podda M; Ghezzi C; Battezzati PM; Bertolini E; Crosignani A; Petroni ML; Zuin M
    Dig Dis Sci; 1989 Dec; 34(12 Suppl):59S-65S. PubMed ID: 2598769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of therapy with bis-hemisuccinate of ursodeoxycholic acid bisodium salt in patients with chronic hepatitis].
    Pinto A; Parini P; Novelli V; Zagari M; Sangermano A; Orsini M; Salzetta A; Buffarini F; Roda E
    Minerva Med; 1992 Jun; 83(6):359-61. PubMed ID: 1352868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of ursodeoxycholic acid treatment on primary biliary cirrhosis].
    Raedsch R; Stiehl A; Hopf U; Möller B
    Z Gastroenterol Verh; 1989 Jul; 24():125-7. PubMed ID: 2474923
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis.
    Batta AK; Salen G; Mirchandani R; Tint GS; Shefer S; Batta M; Abroon J; O'Brien CB; Senior JR
    Am J Gastroenterol; 1993 May; 88(5):691-700. PubMed ID: 8480734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid.
    Güldütuna S; Leuschner U; Imhof M; Zimmer G
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():49-54. PubMed ID: 1449017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis.
    Nilsell K; Angelin B; Leijd B; Einarsson K
    Gastroenterology; 1983 Dec; 85(6):1248-56. PubMed ID: 6628924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bile acids in liver diseases--current indications].
    Stiehl A
    Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of litholytic bile acids on cholesterol absorption in gallstone patients.
    LaRusso NF; Thistle JL
    Gastroenterology; 1983 Feb; 84(2):265-71. PubMed ID: 6848406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey.
    Sarva RP; Fromm H; Farivar S; Sembrat RF; Mendelow H; Shinozuka H; Wolfson SK
    Gastroenterology; 1980 Oct; 79(4):629-36. PubMed ID: 7409382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: results of a controlled study].
    Leuschner U; Fischer H; Hübner K
    Z Gastroenterol Verh; 1989 Jul; 24():133. PubMed ID: 2474926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.